Foghorn Therapeutics Inc. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses), averaging +10.5% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.23 | $-0.10 | +56.5% | Beat | |
| Q1 FY26 | $-0.28 | $-0.29 | -3.6% | Miss | |
| Q4 FY25 | $-0.28 | $-0.34 | -21.4% | Miss |
Back to FHTX overview · FHTX holders · FHTX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.